RenBio joins bigwigs Eli Lilly, Regeneron in hunt for next gen COVID-19 antibodies after $24M financing fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Provided by Business Wire
Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant
MTX-COVAB shows excellent neutralizing activity against original and British variants; ready for clinical development
New antibodies identified with picomolar neutralizing activity against South African variant
Working with Serum Institute India, and prestigious academic partners in Austria, Brazil and South Africa for patient donations to identify additional best-in-class antibodies against all variants of concern
Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7). Memo is now preparing MTX-COVAB for clinical evaluation.
MTX-COVAB, a human-derived antibody against SARS-CoV-2, has shown efficacy against both the original virus as well as the UK variant. Memo is now preparing MTX-COVAB for clinical evaluation. In addition, the company was able to identify a very promising antibody candidate against the South African variant.
Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo Therapeutics can discover novel antibodies at high speed, efficiency and sensitivity derived from recovered patient samples. This approach has enabled the company to also identify a very promising antibody candidate against the South African variant (B.1.351).
Many biopharma companies are betting the novel coronavirus is here to stay and they’re continuing to develop vaccines and drug treatments to keep it under control. They include CureVac, which said the next-gen version of its mRNA COVID vaccine was effective in a rodent study, and Memo Therapeutics, which described the antibody drug candidate it's developing.